SAN FRANCISCO — Stanford University researchers presented autonomous AI 'scientist' agents at the VB Transform 2026 conference on Friday, demonstrating systems designed to accelerate early-stage drug discovery. The presentation drew pharmaceutical executives and venture investors.

The software agents generate hypotheses, design experiments and analyse results in iterative loops. They can narrow vast chemical search spaces faster than conventional pipelines, reducing screening time. The Stanford teams presented case studies in molecular target identification.

VentureBeat hosted the session as part of its annual enterprise AI conference, which increasingly features biotechnology applications. The Stanford presenters stressed that human oversight remains essential for validation, regulatory compliance and safety. Laboratory and clinical testing still govern real-world progress.

The demonstration reflects a broader shift by academic and commercial laboratories to deploy agentic AI in scientific research. Google DeepMind and Isomorphic Labs have pursued related work in protein structure and molecular design. Investors signalled continued appetite for AI-driven biotechnology platforms.

The Stanford researchers identified wider adoption challenges: reproducibility, data quality and integration with existing laboratory infrastructure. They emphasised that peer-reviewed validation of the agents' outputs must precede broader deployment in commercial drug pipelines.